Payment overview · 2025
General Payments
$273.65
14 reported records · 7 companies
Healthcare provider profile · identity verified
Leann Thomas
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SPENCER, WV · NPI 1902344112
Verified facts
What the public records show
CMS Open Payments records show Leann Thomas received $273.65 in general payments during 2025 across 14 reported records.
GENZYME CORPORATION accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $75.73 | 27.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.47 | 25.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.55 | 13.7% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $34.70 | 12.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.16 | 7.4% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $19.00 | 6.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.04 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $273.65 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $75.73 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 150 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 148 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 50 |
| Lisinopril | Lisinopril | 127 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 100 | 30 |
| Gabapentin | Gabapentin | 99 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 38 |
| Omeprazole | Omeprazole | 88 | 30 |
| Buspirone Hcl | Buspirone Hcl | 85 | 27 |
| Potassium Chloride | Potassium Chloride | 85 | 33 |
| Losartan Potassium | Losartan Potassium | 83 | 31 |
| Metformin Hcl Er | Metformin Hcl | 70 | 21 |
| Furosemide | Furosemide | 69 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 23 |
| Trazodone Hcl | Trazodone Hcl | 62 | 25 |
| Metformin Hcl | Metformin Hcl | 61 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 20 |
| Famotidine | Famotidine | 48 | 16 |
| Meloxicam | Meloxicam | 45 | 19 |
| Carvedilol | Carvedilol | 43 | 13 |
| Ibuprofen | Ibuprofen | 41 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 17 |
| Montelukast Sodium | Montelukast Sodium | 40 | 15 |
| Jardiance | Empagliflozin | 39 | 12 |
| Sertraline Hcl | Sertraline Hcl | 38 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Tramadol Hcl | Tramadol Hcl | 36 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 17 |
| Simvastatin | Simvastatin | 35 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | 13 |
| Ozempic | Semaglutide | 31 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Eliquis | Apixaban | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Fluconazole | Fluconazole | 25 | 15 |
| Meclizine Hcl | Meclizine Hcl | 25 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | 11 |
| Cephalexin | Cephalexin | 23 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Olanzapine | Olanzapine | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 12 |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $273.65 · 14 records | GENZYME CORPORATION | AIRSUPRA, BREZTRI, CAPVAXIVE, DUPIXENT, FREESTYLE LIBRE 3, JARDIANCE, Ohtuvayre, WAINUA, WAKIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error